JPWO2020076790A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076790A5 JPWO2020076790A5 JP2021519609A JP2021519609A JPWO2020076790A5 JP WO2020076790 A5 JPWO2020076790 A5 JP WO2020076790A5 JP 2021519609 A JP2021519609 A JP 2021519609A JP 2021519609 A JP2021519609 A JP 2021519609A JP WO2020076790 A5 JPWO2020076790 A5 JP WO2020076790A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 70
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 claims description 10
- 208000008960 Diabetic foot Diseases 0.000 claims description 10
- 101710170970 Leukotoxin Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 206010062255 Soft tissue infection Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010060968 Arthritis infective Diseases 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743501P | 2018-10-09 | 2018-10-09 | |
| US62/743,501 | 2018-10-09 | ||
| PCT/US2019/055144 WO2020076790A1 (fr) | 2018-10-09 | 2019-10-08 | Anticorps dirigés contre les leucotoxines de staphylococcus aureus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512646A JP2022512646A (ja) | 2022-02-07 |
| JPWO2020076790A5 true JPWO2020076790A5 (fr) | 2022-10-18 |
| JP7459075B2 JP7459075B2 (ja) | 2024-04-01 |
Family
ID=68393067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519609A Active JP7459075B2 (ja) | 2018-10-09 | 2019-10-08 | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11059884B2 (fr) |
| EP (1) | EP3864040A1 (fr) |
| JP (1) | JP7459075B2 (fr) |
| KR (1) | KR20210080411A (fr) |
| CN (1) | CN113015745A (fr) |
| AU (1) | AU2019359207A1 (fr) |
| BR (1) | BR112021006704A2 (fr) |
| CA (1) | CA3115765A1 (fr) |
| MX (1) | MX2021004114A (fr) |
| TW (1) | TW202028232A (fr) |
| WO (1) | WO2020076790A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| WO2020076790A1 (fr) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Anticorps dirigés contre les leucotoxines de staphylococcus aureus |
| CN113583119B (zh) * | 2021-07-07 | 2023-05-02 | 西北农林科技大学 | 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒 |
| CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| WO2008103474A1 (fr) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Procédés de production de pharmacothèques, et leurs utilisations |
| BRPI1007005A2 (pt) | 2009-01-29 | 2016-03-22 | Medimmune Llc | anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6 |
| EP3121191B1 (fr) | 2010-05-05 | 2018-09-26 | New York University | Staphylococcus aureus leukocidins, compositions thérapeutiques et leurs utilisations |
| SG192212A1 (en) | 2011-02-08 | 2013-09-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| SG11201503232TA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| CN112316135A (zh) | 2012-11-06 | 2021-02-05 | 米迪缪尼有限公司 | 治疗金黄色葡萄球菌相关疾病的方法 |
| KR20160067977A (ko) * | 2013-10-17 | 2016-06-14 | 알사니스 바이오사이언시스 게엠베하 | 교차반응성 스타필로코커스 아우레우스 항체 서열 |
| ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2016166223A1 (fr) | 2015-04-17 | 2016-10-20 | Arsanis Biosciences Gmbh | Préparation d'une association d'anticorps anti-staphylocoque doré |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| WO2020076790A1 (fr) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Anticorps dirigés contre les leucotoxines de staphylococcus aureus |
| AU2019357983A1 (en) * | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
-
2019
- 2019-10-08 WO PCT/US2019/055144 patent/WO2020076790A1/fr active Application Filing
- 2019-10-08 BR BR112021006704-3A patent/BR112021006704A2/pt unknown
- 2019-10-08 CA CA3115765A patent/CA3115765A1/fr active Pending
- 2019-10-08 TW TW108136342A patent/TW202028232A/zh unknown
- 2019-10-08 CN CN201980074188.5A patent/CN113015745A/zh active Pending
- 2019-10-08 KR KR1020217013374A patent/KR20210080411A/ko unknown
- 2019-10-08 JP JP2021519609A patent/JP7459075B2/ja active Active
- 2019-10-08 MX MX2021004114A patent/MX2021004114A/es unknown
- 2019-10-08 US US16/596,445 patent/US11059884B2/en active Active
- 2019-10-08 AU AU2019359207A patent/AU2019359207A1/en active Pending
- 2019-10-08 EP EP19795711.1A patent/EP3864040A1/fr active Pending
-
2021
- 2021-06-07 US US17/340,622 patent/US11578119B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021105034A5 (fr) | ||
| JP2019527553A5 (fr) | ||
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2017507131A5 (fr) | ||
| JP2020522488A5 (fr) | ||
| JP2017523984A5 (fr) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| CN113015745A (zh) | 针对金黄色葡萄球菌白细胞毒素的抗体 | |
| JP2019205480A5 (fr) | ||
| JP2021155416A5 (fr) | ||
| JP2024105229A5 (fr) | ||
| JP2024029261A5 (fr) | ||
| JP2020518243A5 (fr) | ||
| JPWO2020076790A5 (fr) | ||
| JP2024001073A5 (fr) | ||
| JP2022528387A (ja) | アビド結合多重特異性抗体を作製する方法 | |
| JPWO2020114480A5 (fr) | ||
| WO2023019174A4 (fr) | Anticorps contre le sars-cov-2 | |
| JPWO2021233834A5 (fr) | ||
| JPWO2022111425A5 (fr) | ||
| WO2022037528A1 (fr) | Domaine variable unique et molécule de liaison à l'antigène se liant à bcma | |
| JPWO2020076789A5 (fr) | ||
| RU2021111775A (ru) | Антитела, направленные против лейкотоксинов staphylococcus aureus |